Mr. Doug Janzen reports

AEQUUS EXTENDS COMMERCIAL AGREEMENT FOR SPECIALTY PRODUCT TACROLIMUS IR IN CANADA

Aequus Pharmaceuticals Inc. has agreed to an extension of terms for its promotional service agreement with Sandoz Canada Inc. on tacrolimus immediate-release (tacrolimus IR) to Dec. 31, 2021. Aequus began promotional efforts in December, 2015, for Sandoz's generic tacrolimus, and has since achieved over 10 times growth of the product in Canada through increased brand awareness, new patient adoption programs, and leveraging conversion experience and relationships across provinces.

"We believe there continues to be considerable room for growth over the next 12 months for tacrolimus IR, as we plan continued support for patients and physicians regarding the use of this high-quality and cost-effective alternative to branded tacrolimus," said Doug Janzen, chief executive officer and chairman of Aequus. "This extension of terms is particularly meaningful as well, as it reaffirms our commercial capabilities across specialties, from market access and reimbursement to sales force execution, which is a key driver of growth in our business. Sandoz has been a fantastic partner and while we continue to talk to them about Vistitan and other potential products, this extension allows us to seamlessly continue our efforts on tacrolimus IR while our eye care team focus on the launches of the Evolve products."

About Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals is a growing specialty pharmaceutical company focused on developing and commercializing high-quality, differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage pipeline in neurology.

We seek Safe Harbor.